Today we announced the has agreed with our recommendation that our investigational Celularity Tendon Wrap (CTW) product should be regulated as a device by the FDA Center for Devices and Radiologic Health (CDRH).
Read the full announcement here: bit.ly/3HIHNTQ
Follow
Celularity Inc. (NASDAQ:CELU)
@celularity
A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases. (NASDAQ:CELU)
Celularity Inc. (NASDAQ:CELU)’s Tweets
Today we announced the results of a strategic review of our 2023 key initiatives.
Read more: bit.ly/3wvCTTG
#biotechnology #placenta #crohns #aml #fshd #osteoarthritis #mlasc #nkcell #tcell #cycart19
1
6
Today we announced an exclusive distribution agreement with the Tamer Group, a leading Middle East healthcare distribution company, for our Halal-Certified regenerative biomaterial products in Saudi Arabia.
Read the full announcement here: bit.ly/3CIYag7
2
Today we announced that we have entered into an exclusive territory distribution agreement with CH Trading Group, to act as the exclusive territories distributor of Celularity’s Halal-Certified products in more than 100 countries. Read more: bit.ly/3VZpj5f
1
3
Today we announced a re-analysis of long term follow-up data from three of our legacy studies showed clinically meaningful benefit and durable biological effect in patients with moderate to severe Crohn’s disease warranting further investigation: bit.ly/3ZfpRqv #JPM23
1
6
Today we announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer. Read the full announcement here: bit.ly/3WIdUYB
1
2
The Circle H Sharia Advisory Council issues a groundbreaking ruling for conditional permitted use of stem cells, exosomes, and biomaterials in research, clinical trials and treatment.
Read more: bit.ly/3WfOXUq
3
5
Today released a letter to all stockholders to share some thoughts about ’s work in #osteoarthritis (OA), an important disease in which we are conducting preclinical work.
To learn more, click here: bit.ly/3PAnwC5
1
2
8
#ICYMI: This week shared that it received Halal Certification of our business models, commercial stage biomaterial products & clinical & investigational stage cellular therapeutic programs. To read more about this exciting news, click here: buff.ly/3FrTuwZ
1
2
4
We’re excited to share that has received Halal Certification of our cellular therapeutics, biomaterial products & business model, opening access to Islamic markets globally.
To learn more, click here: bit.ly/3H5tuc3
2
5
Today we presented data from preclinical studies of our placental-derived CYCART-19 T cells in combination with @TeamImugene’s onCARlytics (CF33-CD19) oncolytic virus at SITC. Read the full press release on our website: bit.ly/3NWEIB1
#SITC #Celularity #BioTech
1
8
39
Today we reported our third quarter 2022 financial results and provided a corporate update. Read the press release and hear from our CEO Robert Hariri, M.D., Ph.D. on our website: bit.ly/3G0p31M
3
10
Today we announced that we will present preclinical data on the development of our cell therapy program CYNK-101 in combination with avelumab at The Society for Immunotherapy of Cancer (SITC). Read the release on our website: bit.ly/3UNqXXH
#SITC #Celularity #BioTech
1
8
Today we announced that John R. Haines has been promoted to Senior EVP, General Manager and Chief Administrative Officer, and Brad Glover, Ph.D., has been promoted to EVP and Chief Operating Officer. Read the full press release here: bit.ly/3SWn0Pg
1
2
Today we announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., has been appointed as our new EVP, CMO and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective today. Read the full announcement here: bit.ly/3RlUVzP
1
1
2
Today we announced that will present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 11 a.m. ET. Click here to read the full announcement: bit.ly/3dGFa8P
1
3
8
Today we published new data in Frontiers in Immunology that shows our CYNK cells can recognize and eliminate Influenza A Virus (IAV)-infected Cells in vitro. Read the press release on our website: bit.ly/3LSfuTv $CELU
1
2
7
Today we announced that we have entered into a Pre-Paid Advance Agreement with Yorkville Advisors. Read the press release on our website: bit.ly/3BqLolc $CELU
1
6
Today we announced that will participate in fireside chats at the H.C. Wainwright 24th Annual Global Investment Conference and the Morgan Stanley 20th Annual Global Healthcare Conference. Read the full announcement: bit.ly/3KOPpUC
21
137
Today we reported second quarter 2022 financial results and a corporate update. Read the press release and hear from our CEO on our website: bit.ly/3JFPQA1 $CELU #Q2 #FinancialResults #EarningsRelease #Biotech
1
4
Today $CELU announced the treatment of the first patient in phase 1/2a clinical trial for NK cell therapy CYNK-101, in development for the first-line treatment of advanced #HER2 positive gastric and gastroesophageal junction (G/GEJ) cancers. Read more bit.ly/3cKXz3u
1
14
Today and $CELU announce a pre-clinical research collaboration to evaluate the potential therapeutic synergy combining Antengene's bispecific antibody with our cryopreserved human placental-derived natural killer (NK) cell therapy platform prn.to/3B3ueeQ
1
6
8
We are set to join the broad-market Russell 3000® & Russell 2000® Indexes at the conclusion of the 2022 annual reconstitution, effective after the U.S. market opens on 6/27 according to a preliminary list of additions posted 6/3 bit.ly/3xytQ5K $CELU #Russell
24
180
Today we reported fourth quarter and full year 2021 financial results and a corporate update. Read the press release and hear from our CEO on our website: bit.ly/3qKyObB $CELU #2021FinancialResults #EarningsRelease #Biotech
3
7
23
Our Founder, Chairman, and CEO , and our President, Andrew Pecora, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thu, March 17 at 11:20am ET. Link bit.ly/3JrPYSE $CELU #HealthConference #OPCOHC22 #FiresideChat
2
8
We are pleased to announce that we received #OrphanDrugDesignation from the U.S. FDA for our #CellularTherapy #CYNK-101 for the first-line treatment of advanced HER2/neu positive gastric and gastroesophageal junction #cancer.
Learn more here: bit.ly/3v8ulCX
$CELU
2
44
199
We’re pleased to announce that we received #FastTrackDesignation for our genetically modified NK #CellularTherapy for the treatment of advanced HER2/neu positive gastric and gastroesophageal junction #cancer. Learn more here: celularity.com/celularity-rec $CELU
2
3
16
We received #FastTrackDesignation from the U.S. #FDA for our non-genetically modified #placental derived NK #CellularTherapy in development for the treatment #AML. Learn more about the potential of our #CellularTherapy candidate here: bit.ly/3ewb8RU
2
6
We are pleased to have presented preclinical data on the development of our placental-derived #allogeneic genetically modified #NK and CAR-NK cell therapy programs at the 63rd Meeting and Exposition. Learn more here: bit.ly/3s2siyE
3
12
Today we received #IND clearance from the #FDA for CYNK-101, our genetically engineered #NKCellTherapy candidate designed to synergize with #antibody therapeutics.
Learn more here: celularity.com/celularity-ann
3
15
We are pleased to announce that we have entered into a research collaboration with Oncternal Therapeutics to evaluate ROR-1 targeted placental-derived cellular therapies.
For more details, check out the full press release here: bit.ly/3AqUPzc
1
9
We are pleased to announce that we have entered into a #ResearchCollaboration with to evaluate ROR-1 targeted placental-derived cellular therapies. For more details, check out the full press release here: bit.ly/3AqUPzc
2
7
We’re pleased to appoint Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President of Celularity. In this role, Dr. Pecora will provide senior leadership to help advance our clinical development. For more details, check out the full press release here: bit.ly/3C9PWuQ
2
10
Today, we announced Q2 #FinancialResults for 2021 & provided #CorporateUpdates on our recent merger with GX Acquisition Corp., the expansion of our ongoing Phase 1 trial in patients with #AcuteMyeloidLeukemia & more. Details here: bit.ly/3g7JTy9
4
9
We’re excited to announce a new strategic partnership with to explore a paradigm-shifting approach to #CellularMedicine. Learn more about how we’re striving to extend the reach of #CellularTherapies to #SolidTumors here: bit.ly/2WSwzHb
6
35
We’re thrilled our CEO will be awarded the Pioneer in Medicine Award & the Golden Axon Award by & . Learn more his contributions to #CellTherapy & #COVID19 & the Annual World Congress #SBMT2021 here: bit.ly/3AB9kko
4
8
24
We’re pleased to announce an exclusive supply & distribution agreement with for our placental-derived biomaterial products for #Orthopedics and #SportMedicine in the U.S. bit.ly/3jmtmsL
1
5
14
We’re thrilled to announce the expansion of our Phase 1 clinical trial evaluating our placental-derived unmodified #NKCellTherapy to include patients with relapsed/refractory #AcuteMyeloidLeukemia. Learn about our trial design & initial findings here: bit.ly/3diJ6ZW
7
17
We are excited to welcome Dr. Bradley Glover as Executive Vice President and Chief Technology Officer. Learn more about his expertise and how it will help propel our clinical and preclinical cellular therapy programs here: celularity.com/celularity-app
6